Neuropharmagen trademark for pharmacogenetics SAAS platform

ChangeBridge: Trademarks - Medical Services (Class 044)

Published July 29th, 2024

Detected April 1st, 2026

Summary

USPTO received trademark application TM98671767 for NEUROPHARMAGEN filed by an unspecified applicant on July 29, 2024. The application covers International Class 044 medical services including pharmacogenetic analysis software (SAAS/PAAS), genetic testing and research services, medical diagnostic services, and clinical trial support. The application is filed on an Intent-to-Use basis with a deadline of March 31, 2026.

View original document View source feed page

What changed

USPTO published trademark application TM98671767 for the word mark NEUROPHARMAGEN covering 16 service categories in Class 044 (Medical Services). The application spans software-as-a-service for pharmacogenetic analysis, platform-as-a-service, genetic research and testing services, medical diagnostics, clinical trial support, and related medical reporting services. The Intent-to-Use filing indicates the applicant plans commercial use but has not yet used the mark in commerce.

No immediate action is required by competitors or the public. Third parties have until the publication date plus the standard opposition period to file challenges. The March 31, 2026 date is the applicant's statutory deadline to demonstrate use in commerce or request extension. Healthcare and pharmaceutical companies offering pharmacogenetic services should review whether the mark or its described services overlap with their own offerings or existing trademarks.

Source document (simplified)

← USPTO Trademark Applications

NEUROPHARMAGEN

Intent to Use TM98671767 Kind: intenttouse Mar 31, 2026

Abstract

Software as a service (SAAS) featuring software for analyzing, accessing, and storing information and making recommendations to users in the field of pharmacogenetics; Platform as a Service (PAAS) featuring computer platforms for analyzing, accessing, storing information and making recommendations to users in the field of pharmacogenetics; Science and technology services, namely analysis in the field of pharmacogenetics; Genetic research; Genetic mapping for scientific purposes; Genetic testing for scientific research purposes; Medical and pharmacological research services; Design and development of medical technology; Design and development of computer software for use with medical technology; Pharmaceutical products development; Research laboratory analysis in the field of genetics; Scientific research in the nature of conducting clinical trials for others; Structural and functional analysis of genomes; Research in the field of pharmacogenetics; Information, advice and consultancy regarding all aforementioned services; Medical services; Medical diagnostic services; Medical analysis services for the treatment of persons; Genetic testing for medical purposes; Performing diagnosis of diseases; Medical analysis for the diagnosis and treatment of persons; Remote monitoring of medical data for medical diagnosis and treatment; Genetic analysis in order to increase the efficiency of treatments for patients for medical purposes; Services for the preparation of medical reports, namely, providing information to medical professionals in the form of reports in the field of pharmacogenetics; Information, advice and consultancy regarding all aforementioned services